Genprex, Inc. Banner Image

Genprex, Inc. has reached its limit for free report views

Work for Genprex, Inc.? Upgrade Your Profile and unlock all your annual reports.

Genprex, Inc.

  • Ticker GNPX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Genprex, Inc. Logo Image
  • 1-10 Employees
  • Based in Austin, Texas
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutionsMore and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells.
Genprex, Inc.

Most Recent Annual Report

Genprex, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Genprex, Inc. has reached its limit for free report views.

Older/Archived Annual Reports